Orion Oyj (OTCMKTS:ORINY) Trading Down 0.9% – Here’s What Happened

Orion Oyj (OTCMKTS:ORINY) fell 0.9% during mid-day trading on Tuesday . The stock traded as low as $23.36 and last traded at $23.36. 151 shares traded hands during mid-day trading, a decline of 69% from the average session volume of 488 shares. The stock had previously closed at $23.57.

Orion Oyj Trading Down 0.9 %

The company’s 50-day moving average price is $25.57 and its 200-day moving average price is $23.63. The firm has a market cap of $6.59 billion, a price-to-earnings ratio of 18.54 and a beta of 0.22. The company has a quick ratio of 1.29, a current ratio of 2.39 and a debt-to-equity ratio of 0.31.

Orion Oyj (OTCMKTS:ORINY) last posted its quarterly earnings results on Tuesday, October 29th. The company reported $0.63 earnings per share for the quarter. The firm had revenue of $517.97 million for the quarter. Orion Oyj had a net margin of 23.01% and a return on equity of 41.41%. Equities analysts expect that Orion Oyj will post 1.26 EPS for the current fiscal year.

Orion Oyj Cuts Dividend

The firm also recently declared a dividend, which was paid on Thursday, November 7th. Investors of record on Wednesday, October 16th were given a dividend of $0.2405 per share. The ex-dividend date of this dividend was Wednesday, October 16th. Orion Oyj’s payout ratio is presently 26.19%.

Orion Oyj Company Profile

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson’s disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer.